GlassScriptPhysician profile
Barbara J Bowers
NPI 1578530192
$9,236.45
in general payments reported to CMS, 2019-2025
30 companies · $920 in 2025
The $920 reported for 2025 was more than what 75% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,068 · 2020: $523 · 2021: $1,181 · 2022: $2,912 · 2023: $1,512 · 2024: $1,121 · 2025: $920.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,315 · Long Term Medical Supply Or Device Loan: $140 · Education: $97.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,314.82 |
| Long Term Medical Supply Or Device Loan | $140.00 |
| Education | $97.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $2,810.55 | 2019-2025 | Hydrus Microstent, Clareon, Argos |
| Horizon Therapeutics Plc | $1,844.99 | 2021-2023 | Tepezza |
| Mallinckrodt Hospital Products INC. | $680.55 | 2021-2023 | Acthar |
| Bausch & Lomb Americas INC. | $566.99 | 2022-2025 | Xiidra, Miebo, Envista Envy Iol |
| Glaukos Corporation | $359.42 | 2019-2024 | Idose |
| Johnson & Johnson Surgical Vision, INC. | $336.68 | 2019-2025 | Tecnis Iol, Tecnis Simplicity |
| Sun Pharmaceutical Industries INC. | $325.84 | 2019-2022 | |
| Abbvie INC. | $233.49 | 2022-2024 | Lumigan, Alphagan P, Durysta |
| Biotissue Holdings INC. | $194.09 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $187.02 | 2019-2023 | |
| Sight Sciences, INC. | $161.55 | 2021-2022 | |
| Ocular Therapeutix, INC. | $160.11 | 2023 | Dextenza |
| Shire North American Group INC | $159.53 | 2019 | |
| Oyster Point Pharma, INC. | $157.05 | 2022-2024 | Tyrvaya |
| Allergan, INC. | $147.23 | 2020-2021 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $144.90 | 2023 | Vabysmo |
| Iridex Corporation | $127.17 | 2022 | |
| New World Medical,INC. | $110.76 | 2021 | |
| Apellis Pharmaceuticals, INC. | $83.67 | 2022-2023 | Syfovre |
| Regeneron Healthcare Solutions, INC. | $74.63 | 2022-2023 | Eylea Hd, Eylea |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $74.49 | 2019-2020 | |
| Aerie Pharmaceuticals, INC. | $55.69 | 2020-2021 | |
| Carl Zeiss Meditec USA, INC. | $52.59 | 2022 | |
| Dompe US, INC. | $45.37 | 2025 | Oxervate |
| Alcon Research LLC | $42.79 | 2019 | |
| Eyepoint US, INC. | $31.69 | 2019 | |
| Amgen INC. | $19.88 | 2025 | Tepezza |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Beaver-Visitec International, INC. | $15.48 | 2019 | |
| Astellas Pharma US INC | $12.85 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Barbara Bowers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.